上海信谊联合医药药材有限公司等经营者

Why it is here

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — cartel (monopoly agreement) (上海市市场监督管理局上海市市场监督管理局 · 沪市监反垄处〔2025〕2024002101号; 沪市监反垄处〔2025〕2024002102号; 沪市监反垄处〔2025〕2024002103号; 沪市监反垄处〔2025〕2024002201号 · 市场监管总局发布上海信谊联合医药药材有限公司等经营者达成并实施垄断协议案行政处罚决定书), from 21 March 2025.

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn) — Cartel (monopoly agreement).

Details

Company

上海信谊联合医药药材有限公司等经营者

Authority

State Administration for Market Regulation of China — antitrust (SAMR and provincial AMRs, samr.gov.cn)

Decision

Cartel (monopoly agreement)

Grounds and details, as published

上海市市场监督管理局上海市市场监督管理局 · 沪市监反垄处〔2025〕2024002101号; 沪市监反垄处〔2025〕2024002102号; 沪市监反垄处〔2025〕2024002103号; 沪市监反垄处〔2025〕2024002201号 · 市场监管总局发布上海信谊联合医药药材有限公司等经营者达成并实施垄断协议案行政处罚决定书

From

21 March 2025

Until

—

Status

End date not published

Source

https://www.samr.gov.cn/fldys/tzgg/xzcf/art/2025/art_91753953e0ce4a23a130c67452c477a0.html

Licence

Public antitrust decisions published by the State Administration for Market Regulation of China (samr.gov.cn/fldys)